<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583619</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-000498</org_study_id>
    <nct_id>NCT03583619</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Accelerated Partial Breast Irradiation</brief_title>
  <official_title>A Phase II Randomized Clinical Trial of Accelerated Partial Breast Irradiation Compared With Whole Breast Irradiation With IMRT in Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare radiation toxicity of accelerated partial breast irradiation (ABPI)
      with whole breast irradiation (WBI) in low-risk breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center phase II randomized clinical trial to enroll low-risk breast
      cancer treat with breast-conserving surgery. All eligible patients are randomized to receive
      either ABPI (40Gy/10fx/2wks) or WBI(43.5Gy/15fx/3wks). Intensity modulated radiation therapy
      (IMRT) technique is used. Grade 2 or more acute and late toxicities are prospectively
      evaluated and compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Actual">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number o participants with Grade 2 or more toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>The evaluated toxicities include the following and are evaluated by CTCAE 3.0 criteria:
acute skin toxicity,breast swelling, breast pain,radiation pneumonitis, cardiac toxicity, pulmonary fibrosis, cosmetic result</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>locoregional recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>ipsilateral breast and axillary nodal recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>any death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>any recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant-metastasis survival</measure>
    <time_frame>5 years</time_frame>
    <description>distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with BR-23 questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>BR-23 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasm Recurrence, Local</condition>
  <arm_group>
    <arm_group_label>APBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>APBI</intervention_name>
    <description>Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.</description>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBI</intervention_name>
    <description>Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.</description>
    <arm_group_label>WBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Life Expectation: &gt; 5 years

          -  Enrollment date no more than 12 weeks after breast-conserving surgery or no more than
             8 weeks after adjuvant chemotherapy

          -  Histologically confirmed diagnosis of invasive ductal carcinoma (grade 1-2), or
             mucinous carcinoma, or papillary carcinoma, or tubular carcinoma, or medullary
             carcinoma: primary tumor ≤ 3.0cm in maximum diameter and pN0; or histologically
             confirmed DCIS: primary tumor ≤ 2.5cm in maximum diameter, low-medium grade

          -  Unifocal tumour (confirmed by diagnostic MRI)

          -  No lymphovascular invasion

          -  ER positive (defined as medium-strongly nuclear staining in &gt;1% of the cancer cells)

          -  Negative radial resection margins of &gt;= 2 mm

          -  Surgical clips placed in the tumor bed

          -  Written informed consent.

        Exclusion Criteria:

          -  Stage Ⅱ-Ⅲ

          -  Multifocal tumors

          -  Histologically confirmed diagnosis of invasive ductal carcinoma (grade 3), - - -
             invasive micropapillary carcinoma, carcinoma of lobular in situ, invasive - - -
             lobular carcinoma

          -  Paget's disease of the nipple

          -  Underwent oncoplastic surgery of ipsilateral breast

          -  Underwent neoadjuvant chemotherapy or hormonal therapy

          -  Previous or simultaneous contralateral breast cancer

          -  Undergone ipsilateral chest wall radiotherapy

          -  Active collagen vascular disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shulian Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shu lian Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

